임형순 (Massachusetts General Hospital) | 한빛사논문 > 한빛사

한빛사논문

조회3,972

Massachusetts General Hospital

CV File 111 kb

Proc. Natl. Acad. Sci. USA, May 5, 2015, vol. 112 no. 18 5613-5618 | doi: 10.1073/pnas.1501815112 Digital diffraction analysis enables low-cost molecular diagnostics on a smartphone

Abstract

Hyungsoon Im^a,b,1, Cesar M. Castro^a,c,1, Huilin Shao^a, Monty Liong^a,2, Jun Song^a,d, Divya Pathania^a,b, Lioubov Fexon^a, Changwook Min^a, Maria Avila-Wallace^e, Omar Zurkiya^a,b, Junsung Rho^a, Brady Magaoay^a, Rosemary H. Tambouret^f, Misha Pivovarov^a,b, Ralph Weissleder^a,b,g,3, and Hakho Lee^a,b,3

^aCenter for Systems Biology, Massachusetts General Hospital, Boston, MA 02114;

^bDepartment of Radiology, Massachusetts General Hospital, Boston, MA 02114;

^cMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;

^dSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138;

^eDepartment of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114;

^fDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114; and

^gDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115

Abstract

The widespread distribution of smartphones, with their integrated sensors and communication capabilities, makes them an ideal platform for point-of-care (POC) diagnosis, especially in resource-limited settings. Molecular diagnostics, however, have been difficult to implement in smartphones. We herein report a diffraction-based approach that enables molecular and cellular diagnostics. The D3 (digital diffraction diagnosis) system uses microbeads to generate unique diffraction patterns which can be acquired by smartphones and processed by a remote server. We applied the D3 platform to screen for precancerous or cancerous cells in cervical specimens and to detect human papillomavirus (HPV) DNA. The D3 assay generated readouts within 45 min and showed excellent agreement with gold-standard pathology or HPV testing, respectively. This approach could have favorable global health applications where medical access is limited or when pathology bottlenecks challenge prompt diagnostic readouts.

cancer diagnostics, smartphone, molecular sensing, point-of-care diagnostics, cervical cancer

¹H.I. and C.M.C. contributed equally to this work.

²Present address: Cardno ChemRisk, San Francisco, CA 94105.

³To whom correspondence may be addressed.

Author contributions: R.W. and H.L. oversaw all research studies; H.I., C.M.C., R.W., and H.L. designed individual projects; C.M.C., M.A.-W., O.Z., and R.W. designed clinical studies and obtained samples; H.I., H.S., J.S., D.P., C.M., O.Z., J.R., and B.M. performed research; C.M.C., H.S., M.L., D.P., and J.R. contributed new reagents/analytic tools; H.I., C.M.C., H.S., M.L., J.S., D.P., L.F., C.M., M.A.-W., O.Z., J.R., B.M., R.H.T., M.P., R.W., and H.L. analyzed data; and H.I., C.M.C., R.W., and H.L. wrote the paper.

논문정보

형식Research article
게재일2015년 05월 (BRIC 등록일 2015-05-12)
연구진국외 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기